James Garner

Mr James brings experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses executive leadership and management skills that have seen him achieve outstanding results over a twenty year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Takeda, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sano in Singapore.

Company and Roles

Company
Title
Tenure
Since
PER
Percheron Therapeutics Limited
  • Chief Executive Officer
  • Managing Director
9mthMay 2023

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
29/11/231,000,000N/A6,690,000N/A
PER
Percheron Therapeutics Limited
29/11/231,000,000N/A6,690,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
29/11/23
Issued
6,690,000$0.060$401,400Issue of options
PER
Percheron Therapeutics Limited
29/11/23
Issued
6,690,000$0.060$401,400Issue of options
17/11/23
Buy
100,000$0.061$6,100On-market trade
PER
Percheron Therapeutics Limited
17/11/23
Buy
100,000$0.061$6,100On-market trade
22/08/23
Issued
600,000$0.050$30,000Participation in share purchase plan